First In Class Adoptive Cell Therapies to Cure Patients Carla Biotherapeutics is a Biotech company developing first-in-class adoptive cell therapies tailored to treat diseases with high unmet medical need with a first focus on aggressive life-threatening cancer. Carla Biotherapeutics is founded by a team of seasoned clinicians, cell therapy scientists and biotech professional in Besançon, France with access to a world-class and unique cell-therapy platform. Carla Biotherapeutics’ ambition is to build and develop a pipeline of immunotherapies based on a fully integrated cell therapy platform to discover ena develop adoptive cell therapies tailored to each indication.

40 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AGV Discovery offers services in chemistry, cell biology, in vitro screening, rational drug design, outsourcing and consultancy. AGV Discovery is a pharmaceutics that specializes in rational design and early development of drug candidates.

61 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Biomade Peptides We believe that in the near future peptides have found their way into new markets and are a well-known feed stock for better products in life sciences and beyond. NUMAFERM supports you in these developments – from discovery to commercial production.

66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Science of certainty Founded in 2008, we are a biotech company with two primary areas of business: Preclinical contract research organization (CRO) services and proprietary early target and drug discovery programs. Our focus is the metabolic space (e.g. obesity, diabetes, MASH and gastrointestinal diseases), where we specialize in peptide chemistry, in vivo pharmacology, ex vivo assays, molecular pharmacology, histology, imaging, stereology, NGS (next generation sequencing) and bioinformatics. Gubra is an abbreviation for GUt and BRAin, the original key focus areas of our research and expertise. We work with some of the most interesting and loyal partners and customers from across …

85 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Visionary Care Since 1935 always committed to improve patients’ quality of vision. SIFI is expanding into international market providing innovative solutions for ocular diseases. Eye Care, Pharmaceutical/Nutraceuticals/Medical Devices, Surgical & Diagnostic Medical Devices., Ophthalmology , Science, Researchers , Research, Vision, Eyes, Surgical, Medical technology, Health, Medicine , Eye health , and Biotech

62 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Committed to saving lives. Hemarina is an innovative biotechnology company specializing in health product development based in Morlaix (29600, FR). Our search for new solutions based on the properties of the haemoglobin of the arenicola marina worm is permanent to improve the quality of life of patients and their families. Our commitment: to save lives by putting the patient at the heart of all our actions. BioTech, Ocean, Biomimicry, Biology, Biodiversity, and Transplantation

7 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology

Pioneering next-generation antibody therapies with AI and computational protein design Archon is a biotechnology company developing computationally designed proteins to unlock powerful therapeutic targets that lie beyond the reach of existing modalities and to better treat disease. We directly apply generative protein design to create a new biologic class, Antibody Cages (AbCs), that integrates the industry-proven affinity and specificity of antibodies into self-assembling nanostructures. Precise control over AbC structure provides the ability to tune both how they distribute in the body and engage their cellular targets with high specificity and potency to establish a new gold-standard for biologic medicines. Archon …

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advancing small and large molecule drug discovery with a multimodal AI platform powered by laboratory automation. 1910 Genetics is the only biotechnology company advancing small and large molecule drug discovery with a multimodal AI platform powered by laboratory automation. We integrate AI with three proprietary data streams – computational data, wet lab proxy biological data, and wet lab ground truth biological data – to deliver novel drug candidates and software solutions to leading pharma and tech partners, and advance our internal pipeline for neurological, autoimmune diseases, and cancer. We are backed by leading investors including M12 - Microsoft's Venture Fund, …

89 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Data Analytics Synthetic Biology

Redirecting Immune Memory from Pathogens or Childhood Vaccines to Target Cancer VerImmune is advancing Anti-tumor Immune Redirection (AIR): A Breakthrough Therapy that Redirects Pre-Existing Immune Memory from Childhood Vaccination or Infection to Fight Cancer

188 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Complete genes for complete cures Kano Therapeutics is a biotech startup enabling safe, effective, and flexible correction of gene-length stretches of DNA through a new class of biomaterials: circular single-stranded DNA. By building a “one stop shop” product development platform for single-stranded DNA templates that combines manufacturing, application, and computational tools we bridge the gap between editing genes and totally replacing them. Biotechnology, DNA therapeutics, Gene therapy, CRISPR, and Biological engineering

113 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The first homogeneous immunoassay platform offering unmatched sensitivity with scalable simplicity. Spear Bio, founded in 2021, is a well-funded and rapidly growing start-up headquartered in Woburn, Massachusetts. Spear Bio’s proprietary technology, Successive Proximity Extension Amplification Reaction (SPEAR), employs a unique 2-factor authentication mechanism to precisely measure protein biomarkers at attomolar levels from sub-microliter sample volumes, enabling unprecedented sensitivity. We are dedicated to revolutionizing early disease diagnosis and monitoring, empowering clinicians and researchers to improve patient outcomes, and advance global health. For more information, please visit www.spear.bio or email info@spear.bio. Biotechnology, Ultra Sensitive Immunoassays, and research

60 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

GRObio’s groundbreaking science expands the amino acid alphabet to deliver on the promise of protein-based therapies. GRO Biosciences transforms protein therapeutics with new amino acid building blocks to treat incurable diseases. Protein therapeutics, Biologics, and Genomic recoding

99 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Immunic is a biotechnology company developing small molecule therapies for chronic inflammatory and autoimmune diseases Immunic (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. Privacy Policy: https://imux.com/privacy-policy/

66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The Precision Vaccines Company Belyntic creates novel vaccines for viral diseases with unmet medical need. We have developed and validated a new platform technology, that generates self-adjuvant synthetic long peptides for a safe and durable induction of cellular immunity. Drug development, Cellular immunity, and Platform technology

165 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A Ferring Company working to harness the power of the human microbiome to address unmet medical needs. Rebiotix Inc, part of the Ferring Pharmaceuticals Group, is a clinical-stage biotechnology company revolutionizing the treatment of challenging gastrointestinal diseases by harnessing the power of the human microbiome. Our highly skilled and dynamic team is based out of Roseville, Minnesota. Please feel free to contact us through our website at www.rebiotix.com. Biotechnology, Microbiome, Drug Development, Medicine, Clinical Trials, Regulatory Innovation, Patient Support, Internal Medicine, Manufacturing, Infectious Disease, Gastroenterology, Emerging Diseases, and Novel Technology

64 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. As an organization, Karyopharm is on a mission to improve lives and defeat cancer. In its role as leaders in XPO1 inhibition, Karyopharm delivers on its mission by creating a focused pipeline that targets multiple high unmet need cancer indications, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). oncology, pharmaceutical, biotech, multiplemyeloma, lymphoma, solidtumors, clinicalresearch, clinicaltrials, research, drugdiscovery, medical, and healthcare

40 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A Biotech Company 100% Focused On Advancing New Therapies For Childhood Cancer A life science company exclusively focused on finding cures for childhood cancer by identifying and developing the most promising projects to create new treatments and drugs. drug development, clinical development, and childhood cancer

295 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

ON DEMAND CYTOKINE Company Trutino means ‘Balance’ in Latin, and this represents our strategy, namely an Rx/Dx approach for Precision Oncology Drug & Clinical Development. The company logo symbolizes well balanced wings. As it takes both wings to fly, we believe a balanced Rx/Dx drug development will ultimately deliver on the promise of Precision Oncology. Our effort focuses on ‘targeted destruction of cancer cells’ and simultaneous ‘differential activation of tumor-specific immune cells’ to maximize treatment response. ON DEMAND CYTOKINE, CYTOKINE DRUG, IMMUNO-ONCOLOGY, and TARGETED ONCOLOGY

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A WuXi Advanced Therapies company, based in Oxford, UK. OXGENE, a WuXi Advanced Therapies (WuXi ATU) company, based in Oxford, UK, provides cell and gene therapy pioneers around the world with the technologies, automation platforms and service solutions they need to come first in the race to deliver ground-breaking therapeutics. OXGENETM is headquartered in Oxford, UK. For additional information, please visit our website. PRODUCTS: Largest collection of standardised plasmids on the market and SERVICES: DNA Services, Protein Production Services, Virus Services, Cell Line Development Services.

52 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Our mission is to discover, develop and deliver next generation cancer therapies. G1 Therapeutics, Inc. is a wholly owned subsidiary of Pharmacosmos. Cancer / Oncology, Drug Discovery and Development, and Biotechnology

160 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Taking the Journey Towards Comprehensive Treatment of Serious Disease Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline includes three clinical-stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist and preclinical GIPR modulator programs. For more information, please visit: www.ternspharma.com. Disclaimer: Reposts and posts of contents are for informational purposes only and do not constitute endorsements or promotions of any third-party products, services or organizations (including any statements, views or conducts by such organizations) unless explicitly stated …

71 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Surrozen is a biotechnology company focused on discovering and developing novel regenerative medicines with a focus on unlocking the powerful self-renewal properties of the body through specific control of the Wnt signaling pathway. Surrozen was founded by five leading-edge scientists: K. Christopher Garcia, Ph.D., Roel Nusse, Ph.D. and Calvin Kuo, M.D., Ph.D. from Stanford University; Claudia Janda, Ph.D. from the Princess Maxima Center for Pediatric Oncology; and Hans Clevers, M.D, Ph.D. from the Hubrecht Institute and Princess Maxima Center. Each has conducted extensive research on Wnt signaling, with findings that together shape Surrozen’s technology and approach to therapeutic development. The …

53 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Therapeutics for the Disease of Aging Immune therapy platform targeting Dark Genome antigens that contribute to aging, cancer, diabetes, and neurodegenerative diseases Oncology, Aging, Dark Genome, ALS, Diabetes, and Longevity

198 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

LinKinVax aims at creating a universal, safe, enduring, vaccines platform against multiple pathogens. We are a clinical stage Biotech Spin-off of the Vaccine Research Institute in France with a unique "DC targeting" platform covering infectious desaeses and oncology.

161 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

French biotech company targeting the Adipocyte to treat insulin resistance, type 2 diabetes and associated comorbidities AdipoPharma SAS is a French biotech company with a US subsidiary committed to understanding the role of the adipocyte cells in diabetes via their unique effect on lipid biosynthesis and management of whole-body lipid homeostasis. Our first-in-class candidate - PATAS - is set to enter clinical trials later this year.

75 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Biology x AI-powered drug development platform to transform precision oncology. Orakl Oncology leverages a unique collection of patient tumor avatars that combines biology and clinical data to fuel the therapeutic arsenal to fight cancer. With our platform we partner with oncology players to identify relevant targets and deliver new drugs, faster.

64 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology Data Analytics

Since more than 10 years, AnyGenes® scientists develop and produce innovative high throughput screening products for signaling pathway analysis. These kits and reagents allow high throughput transcriptomic analysis of a large collection of signaling pathways in many species, biomarkers identification and validation, as well as validation of microarrays results. AnyGenes®, with its innovative & cost effective technologies, products and its proprietary molecular platform, helps scientists to accelerate their projects, publications, and biotech companies for drug development and biomarkers validation. Located in Paris, within Tenon Hospital in the 20th arrondissement, AnyGenes® constitutes a key player in the Biotechnology field. Supported by …

21 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Making it possible CLEAN BIOLOGICS is a CDMO for Viral vectors, Viral vaccines and oncolytic viruses and Biosafety testing for biological products. As well as a CMO for MCB & WCB production. GMP compliance

63 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Building a sustainable sector and accelerate the discovery of new treatments tailored to each patient. French consortium to develop new experimental models of cancer in 9 cancer pathologies of interest (Lung, Pancreas, Breast, Liver, Ovary...) 3 major R&D axes: - Developing in vivo models and cell-based assays - Mimicking the human biology by humanizing the tumor microenvironment in mice - Studying the microbiota in cancer patients Oncology, Cancer research, Patient derived Xenograft, Cell lines, Ex vivo assays, Microbiota, Data mining , Translationnal medecine, Humanized mice, Biomarker, Research and Development, In vivo models, Ex vivo models, and Cancer

167 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

2013-2023 In a context where the rate of cancer treatment failure is still unacceptably high, our mission is to provide decision aids to oncologists. We believe that profiling is key to predicting treatment toxicity to patients and effectiveness on tumors. Over a decade of research by the French Atomic Energy Commission (CEA) on the impact of radiations on DNA has resulted in a deep understanding of the essential DNA repair mechanisms. More recently, a set of innovative biomarkers was developed that provides a complete functional signature of these mechanisms, the premise to powerful tools for personalized treatment of cancer. http://www.lxrepair.com …

66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Children with rare diseases deserve therapeutic answers ORPHELIA Pharma is a French pharmaceutical company based in Paris and Lyon that develops and markets medicines for the treatment of pediatric orphan diseases. ORPHELIA Pharma‘s mission is to provide patients with essential products in the fields of epilepsy and pediatric oncology, with formulations adapted to the pediatric population. With one drug approved in the European Union and one product in late-stage clinical development, ORPHELIA Pharma has recently established regional agreements in the European Union, the USA and China and conducts research projects through academic and industrial partnerships. Neurology, Pediatry, Orphan drug, and …

18 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Your Skin Designer LabSkin Creations is a biotechnology company specializing in advanced 3D skin and adipose tissue engineering. By combining innovative cell culture techniques as well as proprietary technologies based on scaffolding biomaterials and 3D bioprinting approaches, LabSkin designs and creates unique and versatile 3D reconstructed models for the performance evaluation of skin and personal care products and their ingredients. tests d'activité et d'efficacité, analyse d'image, Histologie, Immunohistochimie, Biologie cutanée, 3D, Reconstructed skin, and Adipose Tissue

63 similar entities Type: Startup Activities: deeptech industry 4.0 Technologies: Synthetic Biology

Developing the Weapons that we need to defeat cancer. Hephaistos-Pharma is a biotechnology startup developing anti-tumor immunotherapy to revolutionize cancer treatments by spreading the effectiveness of monoclonal antibodies and allowing the treatment of incurable tumors. Oncology, immunotherapy, and cancer

39 similar entities Type: Startup Activities: biotech deeptech

Crossing the next frontier, to give you a fair chance to fight Exeliom Biosciences is a clinical-stage biotechnology company developing next-generation immunotherapies in immuno-oncology and immuno-inflammation. Our novel candidates harness microbiome-associated innate immune regulatory mechanisms. Inflammatory Bowel Diseases, Live Biotherapeutics, Microbiome, Immunotherapies, Immuno-oncology, and Immuno-inflammation

101 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Antineo aims to accompany customers in the preclinical development of novel anticancer agents. We provide services and strategic advice for preclinical development, optimal choice of in vitro and in vivo models as well as strategic input on potential indications to target in the therapeutic landscape. Développement préclinique, in vitro, ex vivo, in vivo, Preuve de concept, Expertise scientifique en pharmacologie, and Modèles à façon

143 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Depixus SAS, based in Paris, is a life science technology company pioneering a groundbreaking technology based on magnetic force spectroscopy. This innovative technology provides real-time analysis of individual biomolecular interactions at scale, enabling researchers to decode disease mechanisms and unlock faster routes to more effective therapies. Single molecule analysis, RNA Drug Discovery, Protein-protein Interaction Analysis, Biophysics, Drug Discovery, Compound Screening, biomolecular interactions, and interactomics

159 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

3D printed personalized medicines MB Therapeutics is a pharmaceutical company that offer patient centric solutions to Develop and produce personalized medicines. MB Therapeutics solution is powered by 3D printing, allowing dosage, shape and API customization in GMP environement Pharmaceutical development, Pharmaceutical 3D printing, and Personalized medicines

63 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

#BeyondInnovation #DermalFiller #CYTOSIAL #AestheticMedicine New ideas, new innovations, new ways of thinking for the medical device industry. We are a pharmaceutical company specialized in the discovery, clinical development, production and commercialization of innovative products in the field of regenerative medicine. At Bioxis Pharmaceuticals, we contribute to transform science into groundbreaking medical device that meet doctors need to improve the health and well-being of their patients in the field of dermatology and aesthetic medicine. Medical Device, Dermatology, Aesthetic, Cosmetic surgery, Regenerative medicine, Ultra-pure chitosan, and Hyaluronic Acid

301 similar entities Type: Startup Activities: healthtech manufacturing deeptech biotech Technologies: Synthetic Biology

33 years of clinical research in pharmacy, medical device & amp; Dermo-cosmetics Quanta Medical Sharing experience Cro since 1986. 30 years of advice and operational services in clinical research and observational studies, 30 years of presence in Europe and on the African continent alongside the pharmaceutical, agro-food, dermatological, cosmetics and medical device, 30 years of human health know -how reinforced by: - a double ISO 9001 & amp; 27001 -dedicated technical tools (Quanta View®, E-CRF, Trial-on-Line®) Clinical research / Clinical trial, E-CRF, Epidemiological Study, Data Management / Biometrics, Medical Writing, Health IT development, Evaluation of health risks, and regulatory advice

249 similar entities Type: SMB Activities: deeptech healthtech Technologies: Synthetic Biology

Advanced Biomaterials for Regenerative Medicine Tensive is a biomedical company developing advanced biomaterials for regenerative medicine applications, with a current focus on reconstructive surgery after breast cancer.

122 similar entities Type: Startup Activities: deeptech healthtech Technologies: New Materials Synthetic Biology

We turn medical devices into clinical reality Neo-Bionica bridges the gap between research and the clinic, providing world-class engineering expertise and links to leading clinicians to create life changing medical device solutions. Offering end-to-end medical device prototype development, from initial concept and rapid prototyping, to pre-clinical testing and first-in-human prototypes for clinical trials

120 similar entities Type: Startup Activities: deeptech healthtech biotech manufacturing Technologies: Synthetic Biology

Doing the extraordinary to restore the ordinary Amber Therapeutics was founded in 2021 with a mission to develop and deliver breakthrough neuromodulation therapies that can fundamentally transform outcomes in areas of unmet clinical need. With the acquisition of Finetech Medical Limited and Bioinduction Ltd in 2023, we are continuing to be the only UK based company in the field of designing and manufacturing long-term implantables. We have since grown into a multidisciplinary team, combining deep medical device experience with a culture and mindset focused on transformational innovation. Amber UI is the company’s first therapy, aiming to restore normal physiological function …

55 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

A nature-inspired solution to trap pathogens @AIS Biotech (with AIS for Anti Infective Sugar) is a French Biotech company based in the @Région Auvergne-Rhône-Alpes, France, incorporated in March 2023 with the objective of developing a new class of sugar-based anti-infective biotherapeutics to fight (re)emerging infectious diseases. Thanks to a Bioengineering plateform based on the expertise of the leading edge academic laboratory @CERMAV (@CNRS, @UGA, Grenoble, France), AIS Biotech aims to develop a pipeline of innovative sugar-based biopharmaceuticals which can prevent or treat infections by mimicking the natural host surface oligosaccharide binding-sites of pathogens. GlycoFlu, our first drug-candidate validated at the …

68 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Your key partner for breakthrough antibody discovery Mabqi specializes in the discovery and development of human therapeutic antibodies. Our core technology is based on proprietary synthetic fully human libraries including pH-sensitive variants tailored for oncology applications. The company offers end-to-end discovery solutions, from antibody discovery, affinity maturation to optimization and full characterization, ensuring tailored support and delivery of high-quality and developable antibodies to meet your needs. Moreover, based on our know-how and technologies, Mabqi is committed to the discovery of therapeutic antibodies on innovative targets with off-the-shelf antibody assets available for partnered development and licensing opportunities. Antibody Discovery, Fully Human …

67 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Shaping the future of in vitro preclinical research Unique R&D platform of donor-derived real human adipose tissue ex vivo for pharmaceutical drug development (obesity, chronic metabolic diseases), dermo-cosmetic, nutraceutical, aesthetic and reconstructive surgery research. ExAdEx-Innov owns exclusive worldwide rights to ExAdEx patented breakthrough technology from French academic laboratories of excellence (Côte d’Azur University, Institut de Biologie Valrose, CNRS, INSERM, University Hospital of Nice) and is supported by SATT Sud-Est, IdEX Université Côte d'Azur, CNRS Innovation, Provence Côte d'Azur Business Incubator, Métropôle Nice Côte d’Azur and Eurobiomed Healthtech Accelerator. adipose tissue, cosmetic testing, research platform, in vitro, ex vivo, models, obesity, …

100 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming cancer and autoimmune treatments with unique IL-1RAP targeting approaches Advesya is a pioneering and transformative biotechnology company developing therapies for difficult-to-treat cancers. Haematology & Oncology, Antibody Drug Conjugate, Cell Therapy, and Autoimmune

398 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Ready -to -use cell bank, for research, for patients Lymphobank - Bank of ready -to -use cells, for research, for patients. Lymphobank is a biotech specializing in the supply of adult and placental -use -for -use blood cells, the characteristics of which will be available online (www.lymphobank.fr), allowing the cellular product to be chosen according to an interest donor. Our services are focused on the development of cellular immunotherapy products. In addition, Lymphobank develops an innovative approach to allogenic adoptive immunotherapy of hepatocellular carcinoma (the most frequent liver cancers and second cause of cancer death in the world, with nearly …

62 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Dedicated to developing treatments for rare diseases originated from nonsense mutations Genvade aims to harness the power of nonsense mutation readthrough molecules to develop treatments for some of the most burdensome rare diseases. Our lead compound targets indications include cystic fibrosis, Duchenne muscular dystrophy and other genetic diseases. small molecules, drug discovery and development, rare diseases, nonsense mutation corrector, cystic fibrosis, genetic diseases, oncology, readthrough, and Duchenne

101 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Adding Quality Years of Life We are dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

207 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Targeting calcium signaling to cure auto-immune diseases KALSIOM is a biotech company founded in April 2020 and based in Brest, France, discovering and developing first-in-class therapies to treat auto-immunes disorders (AID) involving B-cell dysfunction with a high medical need. The company is focusing on developing first-in-class monoclonal antibodies modulating calcium-signaling pathways in lymphocytes. Immunology and Therapeutic antibodies

56 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Neocor is dedicated to pioneering transformative therapies in cardiac care We are currently developing a novel gene therapy approach targeting ischemic and rare genetic cardiac diseases, and moving from lab preclinical trials to regulatory trials. The Company was founded in October and has received strong traction since inception. We will be looking to strengthen our human and financial ressources in the coming month in order to start the regulatory pre clinical trials. gene therapy, biotechnology, rare disease, and cardiology

118 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Smartox Biotechnology is specialized in peptide research and manufacturing Smartox Biotechnology is specialized in peptide research and engineering. Peptide synthesis, physiology, pharmacology, neuroscience, ion channel research, toxin, venomous animals, and screening library

336 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Biomorphic Programmable Polymers TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function. Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, we recognized the exceptional potential for our technology to revolutionize the field of tissue reconstruction in multiple therapeutic areas. Our unique approach to product development leverages the knowledge gained from the development of our technology platform comprised of proprietary polymers, activation technologies, and delivery devices. We have developed a fully …

83 similar entities Tags: FrenchTech120 Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. biotech, medtech, cell therapy, gene therapy, CAR-T, MSC, iPS, ATMP, Tissue Engineering, cell based therapies, biotherapies, RMAT, and Manufacturing

428 similar entities Tags: FrenchTech2030 Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing Tomorrow's Antibacterials Antabio is a privately-held clinical-stage biopharmaceutical company developing novel and highly differentiated antibacterial treatments for drug-resistant infections due to CDC and WHO critical priority pathogens. Please visit www.antabio.com and follow us on Twitter @antabio Antibacterial drug discovery, Drug development, and Antibiotic Adjuvant

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Bioinnovation at your service. Biomedal S.L is a biotechnology company whose mission is to develop and commercialize new technologies, services and products for research, bioindustry and diagnostics. The company develops its activities in two areas: Biomedal Life Sciences and Biomedal Diagnostics. Biomedal Life Science is devoted to the development and commercialization of products and services for life sciences research, and technology for industrial bioprocesses. Its own technology allowed the improvement of recombinant protein production.Biomedal Life Science also functions as a CRO (Contract Research Organization) and provides services and support to pharmaceutical or biotechnology companies. Biomedal Diagnostics offers a large variety …

102 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering Patient-led Antibody Therapeutics Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development. Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies. Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom we partner to further our understanding of disease. Antibody Therapies, Immunology, and Neuro-dengeneration

34 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Inspired by platelet biology to save lives. We engineer and manufacture platelets. platelets, biotechnology, bioengineering, stem cells, on demand, biodrug, in vitro manufacturing, Bioprocess, blood platelets, alloimmunization, thrombocytopenia, blood cancer, leukemia, transfusion, HSCT, Stem cell, Hematology, biologics, drug, biopharma, drug development, healthcare, allogenic therapy, drug delivery, miRNA, siRNA, targeted delivery, and targeted drug delivery

62 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Award-winning Scottish biopharmaceutical company, advancing the treatment of cancers and autoimmune diseases. Medannex is an award-winning Scottish biopharmaceutical company committed to unlocking the therapeutic potential of targeting annexin-A1. Our goal is to create a first-in-class therapy to improve the lives of people impacted by cancers and autoimmune diseases. Following a recent Series B fundraise, and supported by both the Scottish Investment Bank and Innovate UK, Medannex is collaborating with world-leading clinical experts to explore the huge therapeutic and commercial potential of our patent-protected immunomodulatory technology. Antibody development, Innovation, Biotechnology, T cell modulation, Skills development, Autoimmune diseases, Inflammation, Lupus, SLE, Collaboration, …

77 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We are building the world’s leading predictive simulation of patient biology. Truly meaningful medicine comes from breakthroughs?in deeply understanding patient biology. We are building the world’s first open simulation platform of patient biology. Drug Discovery, Biotechnology, Artificial Intelligence, in silico, Cell Biology, Simulated Experiments, Bioinformatics, and Pharmaceuticals

180 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. Synthetic Biology

The Medicine Maker celebrates the people, processes and vision that bring new drugs and biologics to market. The development and manufacture of new drugs and biological medicines draws on the talent, passion and experience of a wide range of professionals. The goal of The Medicine Maker is to bring this group into the limelight and, in doing so, to integrate the entire process, from the registration of an Investigational New Drug (IND) or Biologics License Application (BLA) through to the market launch of new therapies, and beyond. pharmaceutical , biopharmaceutical, bioprocess, upstream, downstream, formulation, drug delivery, and dosage form

138 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Medical cannabis: from seed to purified pharmaceutical grade active ingredients Overseed is the first French biotech company to obtain its license from the ANSM to start its R&D process on cannabis production for pharmaceutical purposes. We are a Biotech which combines leading expertise in genetics, agronomy, organic chemistry and pharma with the ambition to have an expert knowledge on the production of therapeutic cannabis. We will produce GACP and GMP certified dried flowers, full spectrum extracts and purified pharmaceutical grade active ingredients for laboratories. Overseed's research and experimentation will answer patients and the health industry expectations to guarantee production sovereignty, …

58 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Digital bio-solutions designed to support the development of biomedicines and optimize their prescription. mYXpression is an innovative French company positioned in the field of health innovation. The company, specialized in R&D, develops innovative tools to assist in the prescription of biomedicines. Its first tool, the RITI® RA test, provides a personalized report specific to the patient by indicating an efficacy score for each biotherapy. This brand new approach provides numerous useful insights to the doctor by assisting in the prescription of biotherapy in order to increase the patient's chances of remission. bio-numérique, innovation technologique, big data, bio-technologie , biotherapie, intelligence …

59 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: A.I.

marine-inspired molecules to fight immunological diseases Olgram is a biotechnology company developing first-in-class, proprietary immunotherapies to treat immune deficiencies, beginning with immuno-depression after traumatic brain injury and concussion. Biotechnologie, immunologie, antibiorésistance, and commotions

69 similar entities Type: Startup Activities: deeptech biotech

Advanced molecular analysis technologies to harness the power of the microbiota. To be more responsive, more efficient and make better decisions, BforCure allows public and industrial stakeholders to access biological information in real time, thanks to an innovative technology of rapid biodetection.

68 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leading biotech in the development of innovative microbiome-based biotherapies YSOPIA Bioscience is a clinical-stage biotech company developing cutting-edge biotherapies based on the gut microbiome. Our goal is to bring safe & efficient solutions to patients with high unmet medical needs. Microbiome, Obesity, Gut modulator, Cardiometabolism, Cardiometabolic diseases, Microbiota, and Gut microbiota

200 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Syndivia is committed to enhancing treatment options for cancer patients with solid tumors by leveraging the distinctive properties of targeted DAR1 antibody-drug conjugates, which offer improved tumor penetration, stability, and efficacy. Drug development, Biotechnology, Pharmaceuticals, Antibody-drug conjugates, DAR1 ADC, and ADC

156 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Expertise in protein engineering | in silico & in vitro antibody discovery platform We work in partnership with technology platforms, pharmaceutical companies, and academic research groups to create next generation cell and molecular therapies. We integrate novel technologies into a synthetic antibody platform to provide the most advanced discovery engine possible.

259 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

ADVANCED BY NATURE. Ingenza Ltd. is a boutique, employee-owned CRDMO that develops smarter bioprocesses across life sciences and industrial biotech. With over two decades of experience, Ingenza combines molecular biology, biocatalysis, and computational design into a platform-based approach that enables predictable, scalable, and efficient biomanufacturing. At the heart of our offering are proprietary inGenius platform that drive decision-making and accelerate development: codABLETM – our machine learning-driven gene optimization tool for intelligent codon selection and expression tuning Rapid Strain and Cell Line Development – modular workflows for host selection, expression screening, and stability assessment Integrated Process Development – upstream and downstream …

125 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

The Protein Design Company (TM) - new proteins and biochemistry for the production of valuable sustainable molecules Arzeda, The Protein Design CompanyTM, is a synthetic biology company that creates novel proteins, enzymes and specialty chemical products that compete on performance, cost and sustainability. Partnering with Fortune 500 companies, Arzeda has developed a portfolio of enzymes and specialty chemicals for polymers, pharmaceuticals, industrial chemicals and other advanced applications. More information at www.arzeda.com. Synthetic Biology, Bio-based Chemicals, and Protein Design

95 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Centre d'Etudes Biologiques et Pharmaceutiques OUR MISSION: Provide analytical support for all product development phases (human & veterinary medicines + Medical Device) with: Consulting and expertise Formulation development support Analytical method development and validation Stability studies QC testing Veterinary pre-clinical and clinical studies Développement analytique, Etudes de stabilité, Affaires technico-réglementaires, Consulting & expertise, Troubleshooting (pré et post AMM), Etudes précliniques et cliniques vétérinaires, Analytical method development, ICH validation, Stability study, and Quality Control GMP

95 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Science to Transform Lives Immunocore is a leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases. See our community guidelines: http://bit.ly/2kFA8hr Biotechnology, Cancer, Oncology, Infectious Diseases, Autoimmune Diseases, T Cell Receptor, Immunotherapy, ImmTAX, ImmTAC, ImmTAV, and ImmTAAI

264 similar entities Type: Startup Activities: deeptech hrtech biotech Technologies: Synthetic Biology

Tiss’You – Regenerative Company – researches and develops medical devices to upgrade your body’s natural healing ability Tiss'You - Regenerative Company - researches and develops medical devices for regenerative medicine to help doctors and patients with innovative therapeutical solutions. Tiss'You is also a production facility of 850 sqm of which 240 sqm are clean rooms. We have next-generation equipments for R&D, production and quality control; 2 patents, 4 tissue substitutes and 2 point-of-care cell therapy devices. medicina rigenerativa, ricerca e sviluppo, clinica privata, prevenzione, innovazione, ortopedia, chirurgia vascolare, wound healing, lipocell, monocytes, integratori alimentari, regenerative medicine, food supplements, biomaterials, medical …

92 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

The Supramolecular Chemistry Company Aqdot is a Cambridge (UK)-based supramolecular chemistry company with a focus and expertise in developing, licensing and selling novel proprietary products. The Aqdot Solutions part of the business works in partnership with customers to understand their challenges and develop solutions utilising the unique AqBit technology. This has the team working in areas from air filtering in transportation to delivery of therapeutics for cancer. In parallel the Aqdot Products part of the company has recently launched its own brands AqStarTM M1 and Oderase to date. Again, working with partners either on a distribution basis, or offering the …

29 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A cell-therapy technology company developing artificial membrane-binding proteins for oncology and regenerative medicine CytoSeek's mission is to use cell membrane augmentation technology to unlock the potential of next generation advanced therapies. Our novel cell membrane augmentation technology enables us to add new functionalities to various therapeutic cells. CytoSeek is engaged in proof of principle studies to demonstrate enhancement of cell therapies for cancer. We are looking to partner with cell therapy companies to bring these products to the clinic and ultimately enhance human health. Biochemistry, Immunology, Oncology, Regenerative Medicine, Cell therapies, and Proteins

81 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We deliver solutions AdhexPharma is an independent drug delivery company specialized in Transdermal & Topical patches and Oral Thin Films technologies. AdhexPharma is based in France, with GMP manufacturing facility for European and US market. We have 4 approved products in Europe and North America and a pipeline of 6 candidates, ranging from 505(b)2 / NDA and ANDA in different therapeutical areas: pain, CNS, anesthesia, smoking cessation and HRT. Trandermal, Patch, Oral Thin Film, Drug Development, GMP manufacturing, FDA approved, OTF, ODF, cGMP, TDS, CDMO, and CMO

61 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Evexta Bio, formerly #Diaccurate, is a biopharmaceutical company exploring the new frontiers of #oncology in search of daring novel therapeutic approaches with the potential to save lives. Now in the clinic, the French biotech is currently developing two proprietary therapeutic assets with novel mechanisms of action across several indications: - Rupitasertib, formerly DIACC3010, an optimized S6K inhibitor with efficient AKT1/AKT3 control of feed-back loop. The oral anti-tumor agent is expected to enter phase 2/3 clinical trial in refractory ER+ HER2- metastatic breast cancer. - EVX020, formerly DIACC2020, an antibody-drug conjugate program using a sole-in-class KIF20A kinesin inhibitor as payload in …

75 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies. Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology. Our research and development programs target indications with substantial unmet medical needs: NASH, MPS and oncology. Drug Discovery, Biotech, Oncology, Fibrosis, Lysosomal Storage Disorders, NASH, and SSc

154 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Inovative company specialized in the development and manufacture of medical devices EOVE develops and manufactures innovatives products to improve care and quality life with greater freedom for Adult ans Pediatric Patients who suffer from breathing disorders and chronic respiratory diseases.

219 similar entities Type: Startup Activities: healthtech manufacturing deeptech Technologies: Synthetic Biology

PepKon is a french biotechnology company founded in 2022. The company develops first-in-class peptides for the treatment of incurable or poor prognosis cancers. These drug-candidates come from over a decade of academic research, resulting in seven scientific publications and two patent families

134 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Contraline is a venture-backed, clinical-stage biotechnology company at the forefront of male contraception. medical device, biotechnology, urology, contraception, womenshealth, reproductivehealth, and menshealth

136 similar entities Type: SMB Activities: deeptech healthtech Technologies: Synthetic Biology

Utilizing unique protein superglue technology to develop vaccines against infectious disease and cancer worldwide SpyBiotech is a UK-based company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases. SpyBiotech was spun out of the University of Oxford in 2017. Its proprietary protein superglue technology binds antigens to vaccine delivery platforms in a way which minimizes delivery risk and enhances immunogenicity and efficacy. The company’s current lead candidate is against human cytomegalovirus (HCMV), with clinical studies planned for this year. Vaccine Development

62 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A thriving life science community for entrepreneurs and leaders and the ideal environment for businesses to succeed 🧪 Discovery Park is the ideal environment for life science businesses to succeed. From state-of-the-art labs and offices to comprehensive support, we work in partnership with you to provide firm foundations for every stage of your growth. Within easy reach of London, our location provides access to a wealth of resources and opportunities with the freedom to expand, making it the optimal setting for brilliant minds to unlock the potential of scientific breakthroughs. Science, Technology, Manufacturing, Research , Research and Development, Enterprise, Logistics, …

75 similar entities Type: Startup Activities: deeptech manufacturing Technologies: Synthetic Biology

LIVING CURES Prokarium is pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects. Biotechnology, Vaccines, Oral delivery, Immunology, Synthetic Biology, Oncology, Microbial Immunotherapy, and Immunotherapy

125 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The synthetic collagen revolution NVH Medicinal Global Expert in Synthetic Collagen NVH Medicinal is a Dijon -based biotechnology company, created at the end of 2008 whose mission is based on the treatment of pathologies linked to a collagen deficit. It develops products derived from collagen, the most abundant protein in the body and whose dysfunctions cause many diseases (aging, cardiovascular, inflammatory, neurological, fibrosis, cancer and rare diseases). NVH's ambition is to be recognized as an innovative player in the treatment of collagen -related diseases by becoming one of the global leaders in the development, production and marketing of a new …

60 similar entities Type: Startup Activities: deeptech manufacturing Technologies: Synthetic Biology

Your safety passport for cosmetic ingredients & drug candidates Your partner for toxicological risk assessment requests Using our digital solutions increases the product safety and reduces the product development cost up by 30%. Insight Biosolutions (IBS) with his expert network has developed specialized platforms for in vitro and in silico services. IBS develops digital tools and services for the cosmetics and pharmaceutical industries. Computational Toxicology, in vitro toxicology , Safety assessment, Drug Discovery, Molecular Modeling, Computational Chemistry, CPSR, Pre Clinical screening, ADME, and PBPK

83 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Platelet-derived Regenerative Therapy for CNS Disorders InVenis Biotherapies is a biotech compagny, spin-off from academic laboratory U1172 and Taipei Medical University, developping innovative regenerative therapies based on blood platelet. Thanks to the high therapeutic potential of our product, we target the most severe diseases involving cell death, as the amyotrophic lateral sclerosis.

217 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Targeted imaging and therapies Zionexa is an international and innovative company developing and commercializing molecular imaging solutions, in-vivo biomarkers for targeted therapies in oncology, to improve patients’ pathway and bring them a better quality of life. Molecular Imaging, Oncology, Targeted therapies, CDx, Radiopharmaceuticals, and Biomarkers

62 similar entities Type: Startup Activities: biotech deeptech

Dermo-innovation Feeligreen is a technology startup developing safe and effective micro-current devices for a wide range of cosmetic and therapeutic applications. With applications ranging from anti-ageing to wound healing, it develops and sells innovative drug-delivery systems to TIer1 pharmaceutical laboratories medical devices, therapeutics, cosmetics, and skincare

134 similar entities Type: Startup Activities: healthtech manufacturing deeptech biotech Technologies: Synthetic Biology

Innovative medicines to address haemato-oncology related life-threatening and rare diseases ElsaLys Biotech is a specialty pharmaceutical company, part of the Mediolanum Farmaceutici Spa group, focused on innovative medicines to address haemato-oncology related life-threatening and rare diseases. Following strategic acquisitions and targeted developments, ElsaLys is establishing an immunotherapeutic portfolio focused on niche specialty pharmaceuticals to answer unmet medical needs. Our commitment is to offer essential drugs meeting Public Health needs. Founded in 2013, ElsaLys Biotech is located in the heart of the European cluster Lyon Biopole, in Lyon, France. Anticorps thérapeutiques, Anticorps monoclonaux, Therapeutic antibodies, Monoclonal antibodies, ophtalmologie, immune microenvironment, vascular …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Bringing People & Ressources Together The creation of Genbiotech, a spinoff of the Laboratoires Genévrier results of 15 years of strategic involvement in biotechnological research with one goal: to improve the quality of life of patients in the field of rheumatology, dermatology and aesthetic. We believe that tomorrow medicine needs to be dedicated and targeted to patients. We aim to improve existing treatments by using non invasive processes allowing local and sustained administration of biological and active molécules. The company, incepted in 1998, has currently a staff of 11 people and is located in Sophia Antipolis (South of France). For …

58 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

From Sea to Pharmacy ManRos Therapeutics is a biotech company identifying, optimizing and characterizing innovative, low molecular weight kinase inhibitors for the treatment of cystic fibrosis. ManRos was founded in 2007 and is led by Dr Laurent MEIJER, Chairman and CSO, former distinguished Director of Research at the CNRS, and Dr Philippe de Lavenne, CEO, former Vice-President at Actelion Pharmaceuticals. For 40 years, Dr Meijer dedicated his research to the study of protein kinases and their inhibitors, mostly at the CNRS. Drug Development, Cystic Fibrosis, and Biotechnology

60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Science Accelerated KCAS Bio - Lyon (Active Biomarkers) operates as a bioanalytical laboratory based in Lyon, France and headquartered in Olathe, Kansas, USA. We offer comprehensive service solutions for the development of both large and small molecules, with extensive capabilities and expertise in pharmacokinetics, immunogenicity, soluble and cellular biomarker analysis for clinical trials. Operating in state-of-the-art BSL2 facilities, our company is GLP certified and ISO 9001:2015 certified, with a unique track-record in the development, validation, and implementation of analytical methods. Our expert team has supported hundreds of studies in multiple therapeutic areas: oncology, infectious diseases, inflammatory pathologies, and neurodegenerative diseases. …

57 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology Data Analytics

Transforming cancer immunotherapy with next generation ADCs Mablink Bioscience is a French biotechnology company that is actively involved in the fight against cancer by bringing disruptive therapeutic solutions. With its Antibody-Drug Conjugates (ADC) masking technology, Mablink Bioscience aims to dramatically improve the efficiency of ADC therapies and accelerate the development of new treatments. Based in Lyon, where it is developing an unprecedented innovation center, Mablink currently has around 30 employees with diverse backgrounds. biotechnology, drug development, drug discovery, oncology, and R&D

70 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

a NOVARTIS company CELLforCURE gathers all cell and gene therapies activities of the LFB group. With an annual production capability of several thousands of therapeutics batches, the Les Ulis CELLforCURE facility is the first modular entity in Europe to enable large scale industrial production for ATMPs. This platform operates on a mixed model of a CDMO (Contract Development and Manufacturing Organisation) providing large scale GMP and cGMP production services, for both clinical and commercial needs, and of a pharmaceutical company leading the development of cell and gene therapies medicinal products up to their launch on the market. CELLforCURE is an …

87 similar entities Type: Startup Activities: healthtech manufacturing deeptech biotech Technologies: Synthetic Biology

ElyssaMed® will develop the first therapeutic treatment for clinical use comprising several antigenic peptides (epitopes) derived from CTPP and selective for non-small-cell lung cancer, combined with an already marketed vaccine adjuvant. This product once administered to lung cancer patients, will amplify the patients' specific immune responses against tumor cells expressing the antigen CTPP and lead to their destruction.

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Antibody for Therapy AbTx is a preclinical stage biotech company developing the next generation of oncology treatments to treat incurable cancers. AbTx platform is developing mAb innovative enzymatic conjugation. Our platform unlock New Frontiers in Medicine to overcome ADC major drawbacks associated targeting solid tumors by generating antibody Fragment Drug Conjugates (FDCs). ADC, Oncology, and drug develoment

70 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Turning Cancer’s Energy Dependency Against Itself: a Shift in Precision Drug Delivery INATHERYS is a clinical-stage biotech advancing precision drug delivery, turning cancer’s energy dependency against itself. Our lead asset, an ADC targeting CD71/TfR1, is designed to address critical needs in treating proliferative cancers.

60 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

The next generation of of single domain antibodies Emglev is a biotechnology company established in 2023 as a spin-off of Institut Curie dedicated to the discovery and the development of transformative immunotherapies to address unmet medical needs in oncology. By leveraging its unique proprietary platform, expertise and innovative approach, Emglev unlocks the current barriers of conventional antibody discovery to provide unique targets and sdAbs selected fully in vitro and validated for therapeutic applications in any format against any target. At Emglev Therapeutics, we have assembled an experienced, interdisciplinary team with a unique vision : to unlock the next level of …

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

New therapeutic targets based on arsenic trioxide (As2O3) Founded in 2010, MEDSENIC is a biopharmaceutical start-up that aims to exploit the new possibilities offered by the therapeutic use of arsenic trioxide (As2O3) and thereby provide a treatment for patients with autoimmune diseases. santé, biotechnologies, bioparma, biopharmaceutical, biotech, health, biotechnology, autoimmune diseases, and maladies auto-immunes

346 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology